Ibrance
Ibrance ingredients
| Active ingredient | Strength |
|---|---|
| Palbociclib | 125 mg/1, 100 mg/1, 75 mg/1 |
What Ibrance is used for
The FDA lists the approved uses on the official label (below). In the EU, palbociclib is approved as Ibrance for:
Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ibrance
- Generic name
- Palbociclib
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Capsule, Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA207103
- On the US market since
- 2015
Official information
- Ibrance prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Palbociclib)
In India
- Palbociclib: 4 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ibrance?
Ibrance (Palbociclib) is a cancer medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Ibrance?
Ibrance contains Palbociclib (125 mg/1, 100 mg/1, 75 mg/1).
Is Ibrance approved in Europe?
The same active substance is approved in the EU as Ibrance.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA